Low Concentration Fibrinogen Hydrogel for Tissue Adhesion Prevention

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current fibrinogen-based kits for preventing tissue adhesion after invasive procedures often require high concentrations of proteins, which can lead to excessive adhesion formation and discomfort, and lack effective anti-adhesive properties.

Innovation Solution

A kit comprising a fibrinogen-containing component with a concentration range of 5-30 mg/ml and a thrombin-containing component, both with reduced total protein concentrations, is developed to form a hydrogel that effectively reduces tissue adhesion by forming a durable physical barrier with enhanced water retention capabilities.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Strength

If high concentrations of fibrinogen and total protein are used in the kit, then the hydrogel forms a dense structure, but excessive tissue adhesion occurs and anti-adhesive properties are reduced

Engineering Contradiction:
Improvehydrogel structure densityVSAvoidtissue adhesion
Core Design Contradiction:
StrengthVSObject-affected harmful factors

Solution Approach 1:

The patent applies parameter changes by optimizing the concentration ranges of fibrinogen (5-30 mg/ml) and total protein (15-40 mg/ml) to achieve the optimal balance between hydrogel structure density and anti-adhesive properties. This specific concentration range prevents excessive adhesion while maintaining sufficient structural integrity for effective tissue barrier function.

Inventive Principle:
Principle #35Parameter changes

2Object-affected harmful factors

If low concentrations of fibrinogen are used in the kit, then tissue adhesion is reduced, but the hydrogel structure becomes too weak to provide effective barrier function

Engineering Contradiction:
Improvetissue adhesionVSAvoidhydrogel structure integrity
Core Design Contradiction:
Object-affected harmful factorsVSStrength

Solution Approach 1:

The patent resolves this contradiction by establishing a minimum fibrinogen concentration threshold of 5 mg/ml and a maximum of 30 mg/ml, along with corresponding total protein concentrations of 15-40 mg/ml. These parameter boundaries ensure the hydrogel maintains sufficient structural strength while preventing excessive tissue adhesion.

Inventive Principle:
Principle #35Parameter changes

3Productivity

If high total protein concentration is used in the kit, then the hydrogel forms rapidly, but anti-adhesive properties are compromised due to excessive adhesion formation

Engineering Contradiction:
Improvehydrogel formation speedVSAvoidtissue adhesion
Core Design Contradiction:
ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent addresses this contradiction by limiting the total protein concentration to a maximum of 40 mg/ml while maintaining a minimum of 15 mg/ml. This controlled protein concentration range enables adequate hydrogel formation speed while preserving anti-adhesive properties by preventing excessive adhesion formation.

Inventive Principle:
Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The kit demonstrates superior anti-adhesive properties by reducing post-surgical adhesions and maintaining high water retention under pressure, providing a durable barrier that inhibits adhesion formation effectively.

Implementation Method 1

a fibrinogen-containing solution comprising a fibrinogen at a concentration range of between about 5 mg/ml to about 30 mg/ml... and thrombin, under conditions allowing formation of a clot

Methodology Applied
Scientific EffectCoagulation: Coagulation

Data Source

PatentUS11918629B2Low concentrated protein compositions for preventing tissue adhesion
Publication Date: 2024.03.05 OMRIX BIOPHARMACEUTICALS LTD

AI summary

Provided herein are kits comprised of a first container including a solution of fibrinogen-containing component that includes fibrinogen at a concentration range of about 5 mg/ml to about 30 mg/ml, and having a total protein concentration range of about 15 mg/ml to about 40 mg/ml; and a second container that includes a solution of thrombin-containing component. Further provided are mixtures comprised of fibrinogen and thrombin, calcium ions, and albumin, the mixture being comprised of total protein in a range of about 2.5 mg/ml to about 30 mg/ml, fibrinogen in a range of about 50% to about 80% of total protein, and albumin in a range of more than 0.65 mg/ml to about 3 mg/ml. Further provided herein are methods for preventing or reducing tissue adhesion, and hydrogel materials made of fibrin.